A systematic review of the effect of Tranexamic acid in knee and hip arthroplasty
|
|
- Aubrey Turner
- 7 years ago
- Views:
Transcription
1 A systematic review of the effect of Tranexamic acid in knee and hip arthroplasty Christine Schutz Research Coordinator Wakefield Orthopaedic Clinic.
2 Overview Background to how TX works The studies of TX acid in Orthopaedics Results of retrospective study at WOC Blood management in elective THR and TKR surgery. Conclusions re dose of tranexamic acid. Where to from here?
3 Disclosures No conflict of interest Thank you to ANZONA Thank you to Surgeons at WOC
4 National Joint Registry Australia. Annual report Hip Arthroplasty Increasing 4% per year in Australia 37,849 in 2012.
5 Knee Arthroplasty ,385
6 Indications for Joint replacement Pain : severity at rest, distance walking commonly due to Osteoarthritis. Function : Need for a cane, Climbing stairs, Daily living Examination: ROM, Joint stability, other. Radiographic. Joint space limited.
7 Tranexamic Acid Inhibits fibrinolysis by blocking lysine-binding site of plasminogen to fibrin Reduces blood loss and need for Blood transfusions
8 TX ACID Mechanism of Action. Tranexamic acid also know as CYKLOKAPRON in Aust. Given as IV, intra articular, oral, spray., Topical. Found to reduce blood loss in trauma and elective surgery reducing transfusion rates by a third. Is a synthetic lysine derivative that stops the breakdown of fibrin by inhibiting activation of plasminogen. Has a 2 hour half life. Excreted mainly via kidneys.
9 Contraindications for TX use Previous History of DVT Sensitivity to Tranexamic acid Visual problems colour disturbances Poor renal function. COMMON SIDE EFFECTS: Nausea Vomiting and Diarrhoea Dizziness Hypotension Rash (allergic reaction) Over dosage rare.
10 CRASH 2 trial (Trauma) Largest trial published
11 RESULTS CRASH 2 Cause of death TXA Placebo Risk of death P value 10,060 10,067 Bleeding ( ) Thrombosis ( ) Organ failure ( ) 0.25 Head injury ( ) 0.60 Other ( ) 0.63 Any death ( )
12 There was no increase in thrombosis Placebo allocated (10,067) TXA allocated (10,060) Risk ratio (95% CI) DVT 40 (0.40%) 41 (0.41%) PE 72 (0.69%) 71 (0.70%) MI 35 (0.35%) 55 (0.52%) Stroke 57 (0.56%) 66 (0.65%) Any 168 (1.63%) 201 (1.95%) TXA better TXA worse
13 Tranexamic acid dose Same for hips and knees. 15mg/kg initial dose IV Follow 6 8 hrs post surgery
14 CYKLOKAPRON Solution for Injection IV 500mg ampoules in 5ml Water 1000mg ampoules in 10ml Water Tablets available in 500mg (bottle of 100 tabs)
15 Use in Total Knee Arthroplasty meta analysis 16 randomised placebo controlled studies 11 = efficacy (reduced blood loss) Mean age = years N= 365 tranx patients N= 390 controls Cemented and non cemented prosthesis used. Post LMWH Overall dose 10-30mg/kg efficacy shown
16 Knee arthroplasty
17 Topical v Intra articular for TKA Antapur et al Bone and joint (2012) Study Number= 99 pts Randomized to 3 sub groups Doses 1.5, placebo and 3gm. Results: No difference in rate of transfusion between the 1.5g group and placebo The TX group of 3 g = 0 transfusion. 2 out of 99 pts had PE in the 1.5 g group.
18 Meta analysis of TKA trials Cochrane Bone, joint and Trauma J Bone Joint Surg Br 2011 Dec 93 (12 ) Randomized controlled trials. Reduction in allogenic blood transfusion 16% (95% CI : ) Total blood loss 460 mls Concluded that TX was effective and safe for use in TKA and reduced blood loss. Tx does not increase prevalence of DVT or PE.
19 Timing of Administration of TXA minutes before tourniquet released, repeat q 6-8 hrs for first day Nielsen, Ugeskr Laeger 2002 One injection pre-op, one on release of tourniquet Tanaka, JBJS (Br) 2001 Just prior to tourniquet release and 3 hrs later Good, BJA 2003 Oral TX study Repat (50TKA) 25 acid/25 placebo in progress
20 Dose studies Andreau study (71 TKA ) Looked at 2 dose schedules. IV Dose 1. Given IV in theatre 15mg/kg. Dose 2 Given 3 hours post surgery 15mg/kg. Group 1 Showed no Transfusion required in TX group. Group 2 (control) 37 % requiring Transfusion in non TX group.(autologous blood) Tourniquet times mins
21 Arthroplasty Hip and Knee with DVT prophylaxis. Review presented by Blake et al July 2012 Low risk of Thromboembolic Complications N = 2246 primary THA and TKA Dose TX = 1 g IV beginning and at closure. Results: rate of DVT similar across groups p = 0.61 Aspirin alone Warfarin LMWH
22 Dose studies some concerns Lack of information regarding DVT prophylaxis and use of TX acid. 1 st Dose of commencement of injectable LMWH post operatively unclear. Variable dose regimes Multiple confounding variables
23 Imai et al J of Arthroplasty V BLOOD LOSS FOCUS. HIP N= 107 patients. Randomized to 5 groups (Dose and Timing) Found most effective dose for reduction of blood loss for hip arthroplasty 1g TXA given prior to surgery and 6 hrs post. Limited data on risks of DVT
24 TX in hip arthroplasty Limited dose selected studies 6 studies included in meta analysis No studies that used the dose of 60mg/kg. Same dosing is used as for knees. Should be given as slow intravenous infusion Loading dose 50mg/min 1g in 100ml can give at 5ml/min
25 TXA and DVT General consensus. No increased DVTs with TXA Nielsen, Ugeskr Laeger 2002 Tanaka, JBJS (Br) 2001 Good, BJA 2003 Yang J Bone and Joint 2012 TGA report: For every 100 pts knee arthroplasty 6 patients at risk of DVT in TX group.
26 Meta analysis re blood loss Hiipala et al Transfusion risk reduced by 64% Dutch 10 yr Study (Slappendal) 80% less transfusion 40% less infection Decreased morbidity Reduced hospital duration No increase in Thromboembolic events.
27 Trend Of DVT In TX reports. Recent FDA reports. May people reported side effects of TX acid. (Gastro type effects) 31 ie (2.06% ) with DVT Most DVT occurred in < 1 month (88.24%) 1-6 months DVT occurred in %
28 Retrospective study at WOC Review of 354 records Hip (151) Knee (203) 61 m 86m 90 f 117 f
29 RESULTS OF REVIEW WOC HIPs TX Blood and TX Transfusion No TX no Tf
30 RESULTS OF REVIEW WOC Knees Knees 203 TX 54 Blood and TX Transfusio n No TX no TF
31 Adverse events for hip and knees Hypotension (29 H) (17 K) Pulmonary embolism (3 H) Rash (6) Confusion (5)
32 Clinical Perspective Blood management protocol Preoperative: Get sound history of bleeding v clotting Cease supplements eg fish oils etc. Cease NSAIDs antiplatelet meds and aspirin 7-10 days before surgery. Discontinue warfarin 5 days prior check INR Check for preoperative anaemia. Consider iron therapy if <100 ug/l
33 Clinical Perspective Blood management protocol Perioperative management Revising the transfusion trigger to 8Hbg or below has been shown to be safe. Maintain normothermia Surgeon preference re tourniquet and drain. TX given by anaesthetist 15mg/kg before tourniquet release and 2 nd dose surgeon pref.
34 Post operative Clinical Perspective Blood management protocol. Maintain normothermia Limb elevation Withhold thromboprophylaxis until surgical haemostasis (ie 6-8 hrs) Check Hg status transfusion trigger post 8 hr surgery.(<8hgb)
35 Conclusions TX Acid reduces mortality in bleeding trauma patients. Reduces bleeding generally by 25-30% and leads to decreased transfusion rates. TX acid Preoperatively in Total Knee Replacement does not increase incidence of DVT and PE Best dose : how, timing, and dose???? Preoperative anaemia, intraoperative blood loss and post operative care can be influenced by blood management protocols. Audit regularly TX administration. Dose studies needed
36 References Blake et al Clinical orthopaedic Research July 2012 Alvarez J et al Transfusion : Benoni C Acta othopaedics Scand : Naudi Douglas Ralley Clinical Orthopaedics and related research July 2010 V 468 pg 1905 Product Information Cyklokapron p Imai et al Arthroplasty 2012
37 Thankyou
Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies
Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and
More informationPlumbing 101:! TXA and EMS! Jay H. Reich, MD FACEP! EMS Medical Director! City of Kansas City, Missouri/Kansas City Fire Department!
Plumbing 101:! TXA and EMS! Jay H. Reich, MD FACEP! EMS Medical Director! City of Kansas City, Missouri/Kansas City Fire Department! EMS Section Chief! Department of Emergency Medicine! University of Missouri-Kansas
More informationEnhanced recovery programme after TKA through multi-disciplinary collaboration
Enhanced recovery programme after TKA through multi-disciplinary collaboration ChanPK(1), ChiuKY(1), FungYK(6), YeungSS(7), NgT(8), ChanMT(5), LamR(4), WongNY(3), ChoiYY(3), ChanCW(2), NgFY(1), YanCH(1)
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationUncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser
Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationDISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION
DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION Venous thromboembolism is the most common complication after total hip and total knee arthroplasty. In recent times members of the Australian Orthopaedic
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationRandomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
More informationDr NG FU YUEN Associate Consultant Department of Orthopaedics and Traumatology Queen Mary Hospital
Dr NG FU YUEN Associate Consultant Department of Orthopaedics and Traumatology Queen Mary Hospital Aging Population in Hong Kong Life Expectancy Female 86 Male 81 Figure from Census and Statistics Department,
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationPublished 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit
Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationIn recent years there has been an increasing awareness
Chinese Journal of Traumatology 2013;16(2):67-76. 67. Original articles Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials FU De-jie, CHEN Cheng,
More informationTrust Guideline for Thromboprophylaxis in Trauma and Orthopaedic Inpatients
A clinical guideline recommended for use In: By: For: Key words: Department of Orthopaedics, NNUHT Medical staff Trauma & Orthopaedic Inpatients Deep vein thrombosis, Thromboprophylaxis, Orthopaedic Surgery
More informationPosition Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery Position Statement There is currently insufficient data for the (AOFAS) to recommend for or against routine VTED prophylaxis for
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationReview Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty
Thrombosis Volume 2013, Article ID 762310, 5 pages http://dx.doi.org/10.1155/2013/762310 Review Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationEvidence Review. Topic: Same-day Mobilization following Total Hip and Total Knee Arthroplasty
Evidence Review Revised October 01, 2009 Topic: Same-day Mobilization following Total Hip and Total Knee Arthroplasty Background Hip and knee arthroplasty patients routinely receive postoperative physiotherapy
More informationThe New Oral Anticoagulants. Yes
Improving Improving protection protection against against venous venous thromboembolism thromboembolism with new oral anticoagulants with new oral? anticoagulants? The New Oral Anticoagulants will replace
More informationNWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban.
NWMIC Medicines FAQ New oral anticoagulants (NOACs) and management of dental patients - Date prepared: May 2013, updated November 2013 Summary In primary care; Consider liaising with the local hospital
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationSurgery and Anti-Coagulation Agents
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Pre-admission clinics and surgical wards Personnel involved in surgical pre-assessment
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationEach 5 ml ampoule of CYKLOKAPRON solution for injection contains 500 mg tranexamic acid and 5 ml Water for Injections as the inactive ingredient.
PRODUCT INFORMATION CYKLOKAPRON NAME OF THE MEDICINE Tranexamic acid (CAS 1197-18-8) Chemical name: trans-4-aminomethylcyclohexane-carboxylic acid. The empirical formula of tranexamic acid is C 8 H 15
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More information2. Background This indication of rivaroxaban had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationPRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY
PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ON ANTICOAGULANT THERAPY Prepared by: NPSA Anticoagulation Steering Group Approved by: Wirral Drug & Therapeutics Committee 14 th May 2008 Review:
More informationNSQHS Standard 1 Governance
NSQHS Standard 1 Governance Definitions sheet Governance Audit Tools Definitions Contents 1. Open Disclosure Program Page 1 2. ACUTE Clinical Record Audit Tools Page 2 -----------------------------------------------------------------------------------
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationXARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery
XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)
More informationGuideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )
Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-950:2014-2 Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto ) 1.
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationEnoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationHip Replacement. Department of Orthopaedic Surgery Tel: 01473 702107
Information for Patients Hip Replacement Department of Orthopaedic Surgery Tel: 01473 702107 DMI ref: 0134-08.indd(RP) Issue 3: February 2008 The Ipswich Hospital NHS Trust, 2005-2008. All rights reserved.
More informationAntithrombotic therapy
Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be
More informationNew Anticoagulation Agents
New Anticoagulation Agents Use of New and Older Therapeutic Agents in the Treatment Regimen Michelle Geddes Case 1 40 year old woman with idiopathic proximal DVT. Previous heparin allergy (wheals, hives)
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 March 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 ARIXTRA 1.5 mg/0.3 ml, solution for injection in pre-filled syringe Box of 2 (CIP: 363 500-6) Box of
More informationClinical Pathway Total Hip and Knee Replacement
Procedure: THR TKR SIDE: RIGHT LEFT DISCHARGE DESTINATION: HOME INPATIENT REHAB PREADMISSION TARGET DISCHARGE DATE 1. Assessment Preadmission assessment completed Consult: anesthesia or internal medicine
More information0.9% Sodium Chloride injection may be used in most cases.
Table 2. Alternatives to Heparin Sodium in Selected Situations 12-14 Situation Alternative Dose Maintain patency of peripheral venous catheters* 21-26 0.9% Sodium Chloride injection may be used in most
More information! # %# & # ( # # )# # +# ) #,+# ( # ( #!./0 12 % + + # 3 4%. 2 // 4 / 5((6 /07347137 8 0 10/ 010 4 /09 3 % 1030
! # %# & # ( # # )# # +# ) #,+# ( # ( #!./0 12 % + + # 3 4%. 2 // 4 / 5((6 /07347137 8 0 10/ 010 4 /09 3 % 1030 : Litigation after hip and knee replacement in the National Health Service A. B. McWilliams,
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationAre there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More informationGruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
More informationRivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery
for preventing venous thromboembolism after hip or knee replacement surgery (riv-ah-rocks-ah-ban) Summary Rivaroxaban is an oral anticoagulant and the first direct factor Xa inhibitor. Rivaroxaban has
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationTotal Joint Replacement
Total Joint Replacement Brinceton M. Phipps MD Animas Orthopedic Associates 575 Rivergate Lane, Suite 105 Durango Colorado 970-259-3020 www.brincetonphippsmd.com www.animasorthopedics.com Frequently Asked
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationThe Outpatient Knee Replacement Program at Orlando Orthopaedic Center. Jeffrey P. Rosen, MD
The Outpatient Knee Replacement Program at Orlando Orthopaedic Center Jeffrey P. Rosen, MD Anesthesia Pain Management Post-Op / Discharge Protocols The Orlando Orthopaedic Center Joint Replacement Team
More informationCost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip
Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationDATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
More informationRivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism This guidance was developed using
More informationAspirin for use as VTE Prophylaxis in Orthopedic Surgery Patients
Aspirin for use as VTE Prophylaxis in Orthopedic Surgery Patients Pharmacotherapy Rounds March 5, 2009 Erik Peterson, PharmD PGY1 Pharmacy Resident Central Texas Veterans Health Care System The University
More informationNHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY
MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY The scope of this guideline is to simplify the management of patients on oral anticoagulation undergoing major and minor surgery.
More informationHow To Manage An Anticoagulant
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More informationRivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists
Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Traffic light classification- Amber 2 specialist initiation Information sheet for Primary Care Prescribers
More informationTo aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.
UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationOxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Oxford University Hospitals NHS Trust Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for people with a blood clot (thrombus) What is this
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationORTHOPAEDIC INFECTION PREVENTION AND CONTROL: AN EMERGING NEW PARADIGM
ORTHOPAEDIC INFECTION PREVENTION AND CONTROL: AN EMERGING NEW PARADIGM AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS 77th Annual Meeting March 9-12, 2010 New Orleans, Louisiana COMMITTEE ON PATIENT SAFETY PREPARED
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationTherapeutic Class Overview Oral Anticoagulants
Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview/Summary: The oral anticoagulants, dabigatran etexilate mesylate (Pradaxa ), rivaroxaban (Xarelto ), and warfarin (Coumadin, Jantoven
More informationrivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC
rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationConserva)ve Treatment of PE/ DVT
Conserva)ve Treatment of PE/ DVT Amir Kaki, MD FACC FSCAI Asst Prof of Medicine Wayne St SOM Medical Director Cardiac Catheteriza)on Lab Heart Hospital DMC Detroit, MI Incidence Acute pulmonary embolism
More informationΣάββας Σουρμελής Διευθυντής Β Ορθοπαιδικής Κλινικής ΔΘΚΑ «Υγεία»
Σάββας Σουρμελής Διευθυντής Β Ορθοπαιδικής Κλινικής ΔΘΚΑ «Υγεία» 193s Heparin 194s 198s Low-molecularweight heparin Vitamin K antagonists 199s Direct thrombin inhibitors 22 Indirect Xa inhibitor 24 Oral
More informationSurgical Site Infection Prevention
Surgical Site Infection Prevention 1 Objectives 1. Discuss risk factors for SSI 2. Describe evidence-based best practices for SSI prevention 3. State principles of antibiotic prophylaxis 4. Discuss novel
More informationEliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
More informationAdvanced Issues in Peri-Operative VTE Prevention
Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-
More informationOPERATION:... Proximal tibial osteotomy Distal femoral osteotomy
AFFIX PATIENT DETAIL STICKER HERE Forename.. Surname NHS Organisation. Responsible surgeon. Job Title Hospital Number... D.O.B.././ No special requirements OPERATION:..... Proximal tibial osteotomy Distal
More informationTitle of Guideline. Thrombosis Pharmacist)
Title of Guideline Contact Name and Job Title (author) Guideline for patients receiving Rivaroxaban (Xarelto ) requiring Emergency Surgery or treatment for Haemorrhage Julian Holmes (Haemostasis and Thrombosis
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationARTHROSCOPIC HIP SURGERY
ARTHROSCOPIC HIP SURGERY Hip Arthroscopy is a relatively simple procedure whereby common disorders of the hip can be diagnosed and treated using keyhole surgery. Some conditions, which previously were
More informationClinical Guideline N/A. November 2013
State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if
More information